Immunotherapy News and Research

Latest Immunotherapy News and Research

Vaccine suppresses aggregates of tau protein - implications for Alzheimer's

A new study by NYU Medical Center researchers shows for the first time that the immune system can combat the pathological form of tau protein, a key protein implicated in Alzheimer's disease.

22 Aug 2007

Tumors use enzyme to recruit regulatory T-cells and suppress immune response

One way tumors fly under the radar of the immune system is by using IDO, an enzyme used by fetuses to help avoid rejection, to recruit powerful regulatory T cells that turn down the immune response, researchers say.

17 Aug 2007

First biomarker discovered that predicts prostate cancer outcome

Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery.

17 Aug 2007

High-intensity focused ultrasound may alerts the immune system to cancer

An intense form of ultrasound that shakes a tumor until its cells start to leak can trigger an alarm that enlists immune defenses against the cancerous invasion, according to a study led by researchers at Duke University's Pratt School of Engineering.

8 Aug 2007

Interferon alpha and sorafenib combined work better than either alone against kidney cancer

A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study led by Duke University Comprehensive Cancer Center researchers.

1 Aug 2007

Orchestra Therapeutics discontinues HIV vaccine program

Orchestra Therapeutics, Inc. has announced the discontinuation of its HIV Vaccine Development Program.

18 Jul 2007

Harnessing the power of the immune system to fight cancer

Teaching a body's own immune system to seek out and destroy cancerous tumours represents a promising way to fight a disease that kills more than 70,000 Canadians a year.

4 Jul 2007

The next era of cancer treatment

Teaching a body's own immune system to seek out and destroy cancerous tumours represents a promising way to fight a disease that kills more than 70,000 Canadians a year.

4 Jul 2007

Discovery of method to identify how cancer evades the immune system

One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.

3 Jul 2007

Biovest announces interim blinded data of fast-tracked pivotal phase 3 clinical trial of BiovaxID

Biovest International announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006.

29 Jun 2007

Umbilical cord blood may safely preserve insulin production in children newly diagnosed with type 1 diabetes

University of Florida researchers sought to determine whether it is feasible to use a patient's own cord blood stem cells to neutralize the body's autoimmune attack on the pancreas and help restore the organ's ability to make insulin, which regulates how the body uses sugar and other nutrients for energy.

27 Jun 2007

Newly found antibodies may be body's natural defense against Alzheimer's

In an important advance in the battle against Alzheimer's disease, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have identified naturally occurring antibodies in human blood that may help to defend against this form of dementia as well as other neurodegenerative diseases.

14 Jun 2007

Protein S-100 linked to melanoma recurrence

Higher levels of a protein called S-100 in patients with melanoma may correlate with a higher risk of having the disease return, say researchers at the University of Pittsburgh Cancer Institute (UPCI), who presented their findings today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

5 Jun 2007

Findings from study of immunotherapy vaccine in prostate cancer patients

Data from an ongoing study designed to explore the biologic and clinical activity of cancer immunotherapy sipuleucel-T, or Provenge, in patients with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic disease will be presented by Oregon Health & Science University Cancer Institute researchers.

5 Jun 2007

Blood of bird flu survivors promises new treatment for the deadly virus

Scientists are optimistic that blood donated by four survivors of bird flu will offer some clues as to why some people appear to have protection against the deadly H5N1 virus.

29 May 2007

Immune antibodies penetrate neurons to clear Alzheimer's-linked amyloid

Researchers at Weill Cornell Medical College have gotten much closer to understanding how immune-based therapies can treat Alzheimer's disease -- by studying how antibodies go inside brain cells to reduce levels of Alzheimer's-linked amyloid peptides that form plaques between neurons.

24 May 2007

New understanding of how immune-based therapies can treat Alzheimer's disease

24 May 2007

Right medications essential for allergy control

Choosing the right medications is essential to gaining control over symptoms as allergy season comes into full bloom, allergy specialists at UT Southwestern Medical Center warn.

10 May 2007

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech has announced results of in vitro cytotoxicity and in vivo pharmacokinetic studies conducted to evaluate the potential for combining its phase III anti-cancer antibody therapeutic, Proxinium, with first-line standard of care therapy for squamous cell carcinoma of the head & neck (SCCHN).

19 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007